ITMCTR2000003377尚未招募未知
Clinical efficacy and immune mechanism of yifeiyin in delaying TKI resistance in non-small cell lung cancer
Tongde Hospital of Zhejiang Province0 个研究点开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 年龄范围
- 18 至 70(—)
- 性别
- All
入选标准
- •1. Patient with stage IIIB to IV lung cancer which was diagnosed by CT, MRI, B-ultrasound and other imaging examinations, and confirmed by cytology or pathological examination;
- •2. Adopted the ADx-ARMS-EGFR gene mutation detection kit (Xiamen Aide Biomedical Science and Technology Co., Ltd. 21 human EGFR gene mutation detection kits) to be confirmed as EGFR gene sensitive mutation patients undergoing EGFR-TKI treatment;
- •3. TCM syndrome differentiation belongs to spleen deficiency phlegm and dampness type;
- •4. Can follow the doctor's instructions (take spleen deficiency phlegm and dampness medicine for more than 3 months), insist on taking medicine, good compliance, can understand the situation of this study
- •Patients who have signed an informed consent form;
- •5. Age 18 to 70 years; PS score <=2 points;
- •6. No dysfunction of major organs, normal blood routine, liver, kidney and heart function: hemoglobin >=9 g/L, neutrophil absolute cell count (ANC) >=1.5x10^9/L, platelet >=100x10^9/L, Bilirubin <=1.5 ULN, alkaline phosphatase ((APL), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <=2.5 ULN (if liver metastasis is allowed ALT <=5 ULN ). International normalized ratio (INR) <=1.5 ULN. Activated partial thromboplastin time (APTT) <=1.2 ULN, creatinine <=1.5 ULN.
排除标准
- •1. Have a history of other tumors within 5 years;
- •2. Those whose expected survival time is less than 3 months;
- •3. Patients with any acute or chronic diseases or mental disorders or abnormal laboratory tests, these combined diseases may increase the risk of participating in research or research medication, or have an impact on the research results. The investigator judges that the patient is not suitable for joining the study,these situations include:(Uncontrolled high blood pressure, unstable angina, myocardial infarction, or symptomatic congestive heart failure or uncontrolled arrhythmia in the past 12 months. Electrocardiogram suggests significant changes in ischemia; bacterial, fungal, or viral infections The active period of the disease; those with dementia or major changes in mental state that make it impossible to understand or express informed consent);
- •4. Patients during pregnancy or lactation;
- •5. Those who have poor compliance with the protocol and the researchers believe that it is not appropriate to participate in this experiment;
- •6. Those who are allergic to drugs or are participating in other drug trials.
研究者
相似试验
尚未招募
1 期
Clinical Study of therapeutic effect of Yuyinyanggan decoction on patients of primary biliary cholangitis with 25-OH-D by LC-MS/MSITMCTR2000004008Shanghai Municipal Hospital of Traditional Chinese Medicine
招募中
1 期
Clinical efficacy and immune mechanism of Bushen Yifei Decoction in the treatment of stable chronic obstructive pulmonary diseaseITMCTR2000003760Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
招募中
4 期
Clinical study on the efficacy and safety of Jieyuwan in the treatment of epidemic stress, anxiety and depression (stagnation of liver Qi syndrome)Anxiety and depressionITMCTR2100004368Dongfang Hospital Beijing University of Chinese Medicine
尚未招募
1 期
Study on the Therapeutic Effect and Mechanism of Yinaokang on Post-stroke Cognitive Impairment No DementiaITMCTR2000004178GuangDong Provincial Hospital of Chinese Medicine
尚未招募
不适用
Clinical efficacy and Therapeutic Mechanism of Yiqihuoxuetongqiaomingmu recipe in the treatment of non-Arterial Ischemic Optic Neuropathy (NAION)ITMCTR1900002774the first affiliated Hospital of Guangzhou University of Chinese Medicine
